Asston Pharmaceuticals
Asston Pharmaceuticals (APL) share price was ₹146.25 at the 28 Oct 2026 close; market capitalisation ₹160 Cr; sector Capital Goods. The share price rose 74.1% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Mar 2026 quarter, revenue rose 10.8% year on year to ₹10.05 Cr and net profit fell 75.4% year on year to ₹0.48 Cr (compared with Mar 2025). Promoters held 39.48% of Asston Pharmaceuticals in Sep 2026, down 11.18 percentage points from Mar 2026. Its Tapetide Score is 46/100 (Average) as of 28 Oct 2026.
Key Fundamentals
SMEElectrical EquipmentCapital GoodsPrice-based figures as of 28 Oct 2026, 15:30 IST · TTM
Peer Comparison
Healthcare › Capital Goods › Other Electrical Equipment › Pharmaceuticals
| ₹1,766.10 | 35.03 | 4,23,747 Cr | 5.07 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,626.00 | 87.37 | 2,55,540 Cr | 15.25 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,596.10 | 72.15 | 1,74,821 Cr | 9.51 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,183.80 | 107.90 | 1,17,993 Cr | 22.26 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,180.50 | 26.27 | 1,17,755 Cr | 4.34 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,340.80 | 34.73 | 1,11,914 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,370.90 | 32.84 | 1,10,749 Cr | 3.13 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Asston Pharmaceuticals (this company) | — | — | 160 Cr | 2.40 | 0.00% | 9.95% | 12.25% | — | — |
| Median 8 companies | ₹1,766.10 | 35.03 | 1,17,874 Cr | 4.71 | 0.47% | 12.98% | 16.41% | 28,515 Cr | 3,184 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 81/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company has reduced debt.
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
Weaknesses
6- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -11.2%
- Promoter holding is low: 39.5%
- Earnings include an other income of Rs.6.07 Cr.
- Company has high debtors of 524 days.
- Working capital days have increased from 258 days to 434 days
Technical Indicators
Oscillators
Bearish
Overall
Bullish
Moving Averages
Bullish
Growth Rate
change over 1 year
change over 1 year
change over 1 year Operating margin -27.86% · Mar 2026
Quarterly Results
| Particulars | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 15.97 | 9.07 | 15.42 | 10.05 |
| Expenses | 13.71 | 5.89 | 13.19 | 12.85 |
| Operating Profit | 2.26 | 3.18 | 2.23 | -2.8 |
| OPM % | 14.15% | 35.06% | 14.46% | -27.86% |
| Other Income | 0.64 | -0.07 | -1.86 | 4.63 |
| Interest | 0.42 | 0.53 | 0.28 | 0.36 |
| Depreciation | 0.02 | 0.02 | 0.07 | 0.25 |
| PBT | 2.46 | 2.56 | 0.02 | 1.22 |
| Tax % | 22.76% | 23.44% | -50% | 59.84% |
| Net Profit | 1.9 | 1.95 | 0.03 | 0.48 |
| EPS (₹) | 3.02 | 3.11 | 0.04 | 0.56 |
Profit & Loss
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 9.6 | 6.54 | 16.03 | 25.04 | 25.47 |
| Expenses | 9.96 | 5.02 | 12.21 | 19.6 | 25.99 |
| Operating Profit | -0.36 | 1.52 | 3.82 | 5.44 | -0.52 |
| OPM % | -3.75% | 23.24% | 23.83% | 21.73% | -2.04% |
| Other Income | 0.96 | 0.65 | 0.25 | 0.57 | 6.07 |
| Interest | 0.43 | 0.72 | 0.76 | 0.95 | 0.63 |
| Depreciation | 0.01 | 0.04 | 0.06 | 0.04 | 0.32 |
| PBT | 0.16 | 1.41 | 3.25 | 5.02 | 4.6 |
| Tax % | 31.25% | 25.53% | 25.23% | 23.11% | 15.87% |
| Net Profit | 0.11 | 1.06 | 2.43 | 3.85 | 3.87 |
| EPS (₹) | 0.2 | 1.89 | 3.86 | 6.14 | 4.55 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 0.7 | 0.7 | 0.78 | 6.27 | 8.51 |
| Reserves | 0.23 | 1.29 | 6.4 | 4.76 | 30.35 |
| Borrowings | 3.31 | 5.24 | 6.82 | 7.26 | 5.1 |
| Other Liabilities | 5.25 | 6.46 | 6.7 | 9.83 | 7.69 |
| Total Liabilities | 9.49 | 13.69 | 20.7 | 28.12 | 51.65 |
| Fixed Assets | 0.92 | 1.13 | 0.97 | 0.96 | 10.69 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 8.57 | 12.56 | 19.73 | 27.16 | 40.96 |
| Total Assets | 9.49 | 13.69 | 20.7 | 28.12 | 51.65 |
Cash Flow
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | -1.19 | -0.32 | -3.97 | -0.03 | -10.18 |
| Investing | 0 | -0.91 | -0.01 | 0.73 | -9.91 |
| Financing | 1.29 | 1.21 | 3.86 | -0.51 | 21.18 |
| Net Cash Flow | 0.1 | -0.01 | -0.12 | 0.19 | 1.09 |
| Free Cash Flow | -1.19 | -0.57 | -3.98 | 0.68 | -20.24 |
| CFO/EBITDA | 322 | -20 | -92 | 0 | 1,500 |
Ratios
| Particulars | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 243 | 481 | 381 | 358 | 524 |
| Inventory Days | 27.24 | 204 | 53.91 | 18.59 | 16.14 |
| Days Payable | 247 | 755 | 218 | 157 | 121 |
| Cash Conversion Cycle | 23.79 | -69.7 | 217 | 220 | 419 |
| Working Capital Days | -12.17 | 43.53 | 163 | 177 | 434 |
| ROCE % | — | 37.14% | 37.78% | 36.61% | 16.96% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Asston Pharmaceuticals insights
58 extracted metrics + investor summaries across FY22–FY26.
Documents
Frequently Asked Questions about Asston Pharmaceuticals
What does Asston Pharmaceuticals Ltd do?
Where is Asston Pharmaceuticals Ltd (APL) listed?
Which sector does Asston Pharmaceuticals Ltd belong to?
What is the market capitalisation of Asston Pharmaceuticals Ltd?
What is the 52-week high and low of Asston Pharmaceuticals Ltd?
What is the Return on Equity (ROE) of Asston Pharmaceuticals Ltd?
Company Information
Incorporated in 2019, Asston Pharmaceuticals Ltd is in the business of manufacturing pharmaceutical products.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544445.md for Asston Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.